Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Completed · Phase 1
Conditions studied: Leukemia, Myelodysplastic Syndromes
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of dolastatin 10 in treating patients who have refractory or relapsed acute leukemia, chronic myelogenous leukemia in blast phase, or myelodysplastic syndrome.
Key facts
- Study ID
- NCT00003693
- Run by
- M.D. Anderson Cancer Center
- People needed
- 30
- Starts
- 1998-12-18
- Expected to finish
- 2001-10-30
- Last updated by the study team
- 2018-10-25
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.